Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, and College of Medicine, Chang Gung University, Kaohsiung, Taiwan.
Subst Abus. 2012;33(4):366-72. doi: 10.1080/08897077.2011.638736.
Paramethoxymethamphetamine (PMMA) is an emerging and prevalent psychoactive drug with a structure analogous to amphetamine and related psychostimulants. However, the neurobehavioral effect is only studied in experimental animals and is barely mentioned in human. The authors report the antemortem neurobehavioral manifestations in 8 patients with PMMA use. There were 2 different antemortem presentations. The first group of patients showed delirium, hypertalkativity, and incoherence speech and then turned into convulsion and death. They did not exhibit the typical hyperdopaminergic movement disorder. The second group of patients gradually fell asleep and then suffered respiratory or cardiovascular collapse. The heart blood PMMA level was higher in the second group than in the first group of patients. Forensic autopsy showed variable findings, ranging from no remarkable change to significant pathological damage similar to serotonin syndrome in both groups of patients. PMMA seems to enhance serotoninergism than dopaminergism, and exerts a concentration-related dual effect on human.
对苯丙胺（PMMA）是一种新兴且流行的精神活性药物，其结构类似于苯丙胺和相关的精神兴奋剂。然而，其神经行为效应仅在实验动物中进行了研究，在人类中几乎没有提及。作者报告了 8 例 PMMA 使用患者的生前神经行为表现。有 2 种不同的生前表现。第一组患者表现为谵妄、多动、言语不连贯，然后转为抽搐和死亡。他们没有表现出典型的高多巴胺能运动障碍。第二组患者逐渐入睡，然后出现呼吸或心血管衰竭。第二组患者的心血 PMMA 水平高于第一组。法医尸检显示两组患者的发现各不相同，从无明显变化到与两组患者的 5-羟色胺综合征相似的明显病理损伤。PMMA 似乎增强了 5-羟色胺能作用而不是多巴胺能作用，并对人体产生浓度相关的双重作用。
